SDStephanie M. Delgado

Stephanie M. Delgado

*This is an algorithmically generated author record based on publicly available information.

Stephanie M. Delgado has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Upgrading expandable leadless pacemakers from single- to dual-chamber

    by Maria Grazia Bongiorni, Rahul Doshi, James E Ip, Derek V Exner, Vivek Y Reddy, Pascal Defaye, Robert Canby, Morio Shoda, Gerhard Hindricks, Mayer Rashtian, et al.

    Aims: The aim of this analysis was to evaluate the upgradeability of a single-chamber leadless pacemaker (LP) to a dual-chamber system in patients indicated for a dual-chamber pacemaker. Methods and results: A prospective, multicentre study evaluated the safety and performance of a dual-chamber LP. The study included patients with a prior ventricular LP to evaluate its upgradeability. Patients had an attempted atrial LP implant, and if successfully implanted, the LPs were paired to a dual-chamber pacing mode to evaluate upgrade success. Patients were followed for 12 months from the attempted atrial LP implantation. Among 35 patients with an attempted upgrade (62.9% male, average age 70 years), the most common primary indication was sinus node dysfunction (57.1%). Out of 35 patients, 91.4% had successful upgrades. The mean atrial device electrical measurements stabilized within 1 month from the procedure and remained stable through 12 months (capture threshold at 0.4 ms 0.8 ± 0.6 V, sense amplitude 4.5 ± 2.7 mV at 12 months). A total of five (14.3%) patients experienced seven complications, all of which were procedure-related. There were no device or procedure-related deaths. The total estimated battery longevity (accounting for time since implant) evaluated at 12 months was 11.3 ± 4.2 and 5.7 ± 2.6 years for the ventricular and atrial LPs, respectively. One patient required an atrial LP revision 10 months after implantation. The LP was retrieved and replaced. Conclusion: These data confirm the feasibility, safety, and long-term effectiveness of adding an atrial LP in patients with a pre-existing ventricular LP to achieve dual-chamber leadless pacing.


  • Open Access

    Worldwide Chronic Retrieval Experience of Helix-Fixation Leadless Cardiac Pacemakers

    by Petr Neuzil, Derek V. Exner, Reinoud E. Knops, Daniel J. Cantillon, Pascal Defaye, Rajesh Banker, Paul Friedman, Chris Hubbard, Stephanie M. Delgado, Anuradha Bulusu, et al.


  • Open Access

    Patient Preferences for Features Associated With Leadless Versus Conventional Transvenous Cardiac Pacemakers

    by Shelby D. Reed, Jui-Chen Yang, Matthew J. Wallace, Jessie Sutphin, F. Reed Johnson, Semra Ozdemir, Stephanie M. Delgado, Scott Goates, Nicole Harbert, Monica Lo, et al.

    BACKGROUND: Regulatory approval of the first dual-chamber leadless pacemaker system provides patients an alternative to conventional transvenous pacemakers. The study objective was to quantify the preferences of patients for pacemaker features. METHODS: Patients with a de novo (ie, initial) pacemaker indication were recruited from 7 US sites to complete a Web-based discrete-choice experiment survey between May 11, 2022, and May 24, 2023. Patients chose between pairs of experimentally designed, hypothetical pacemakers that varied according to type (removable leadless, nonremovable leadless, or conventional transvenous); battery life (5, 8, 12, or 15 years); time since regulatory approval (2 or 10 years); discomfort for 6 months (none or discomfort); and complication risk and infection risk (1%, 5%, or 10%/20% for each). Patients’ choice data were analyzed using random-parameter logit models and latent-class analysis. RESULTS: Among 117 participants, the mean (SD) age was 67.3 (14.6) years, 94% were white, and 42% were female. On average, patients’ survey responses revealed a preference for removable leadless pacemakers (β, 0.340; SE, 0.096) over both nonremovable leadless pacemakers (β, −0.310; SE, 0.131; P =0.001) and conventional transvenous pacemakers (β, −0.030; SE, 0.119; P =0.031). However, latent-class analysis revealed 2 distinct preference classes. One class preferred leadless pacemakers (50.5%), and the other class preferred conventional transvenous pacemakers (49.5%). The conventional pacemaker class prioritized pacemakers with 10 rather than 2 years since regulatory approval ( P P =0.83). Complication risks and infection risks were found to be the most influential. All else equal, patients would accept maximum risks of complications or infections ranging about 5% to 18% to receive their preferred pacemaker type. CONCLUSIONS: Latent-class analysis revealed strong patient preferences for the type of pacemaker, with a nearly equal split between recent leadless pacemaker technology and conventional transvenous pacemakers. These findings can inform shared decision-making between health care providers and patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05327101.


  • Open Access

    Externalized conductors and electrical dysfunction in transvenous ventricular leads: Results of the Cardiac Lead Assessment Study

    by Roger A. Freedman, Anne B. Curtis, Stephanie M. Delgado, Li-Yin Lee